WO2009063081A3 - Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc. - Google Patents

Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc. Download PDF

Info

Publication number
WO2009063081A3
WO2009063081A3 PCT/EP2008/065618 EP2008065618W WO2009063081A3 WO 2009063081 A3 WO2009063081 A3 WO 2009063081A3 EP 2008065618 W EP2008065618 W EP 2008065618W WO 2009063081 A3 WO2009063081 A3 WO 2009063081A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
ckc
therapeutic agent
nucleosidic moiety
nucleosidic
Prior art date
Application number
PCT/EP2008/065618
Other languages
French (fr)
Other versions
WO2009063081A2 (en
Inventor
Grégory LAMBERT
Frédéric Lallemand
Original Assignee
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/939,840 external-priority patent/US7834172B2/en
Priority claimed from EP07301550A external-priority patent/EP2060262B1/en
Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa
Publication of WO2009063081A2 publication Critical patent/WO2009063081A2/en
Publication of WO2009063081A3 publication Critical patent/WO2009063081A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition comprising at least one nucleosidic moiety and cetalkonium chloride and pharmaceutical use thereof for prevention, treatment or relief of eye, lung, and/or respiratory tract conditions.
PCT/EP2008/065618 2007-11-14 2008-11-14 Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc. WO2009063081A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/939,840 US7834172B2 (en) 2007-11-14 2007-11-14 Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC
US11/939,840 2007-11-14
EP07301550A EP2060262B1 (en) 2007-11-14 2007-11-14 Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc
EP07301550.5 2007-11-14

Publications (2)

Publication Number Publication Date
WO2009063081A2 WO2009063081A2 (en) 2009-05-22
WO2009063081A3 true WO2009063081A3 (en) 2009-09-24

Family

ID=40639235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/065618 WO2009063081A2 (en) 2007-11-14 2008-11-14 Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.

Country Status (1)

Country Link
WO (1) WO2009063081A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096287A1 (en) * 1998-05-21 2005-05-05 Mehta Rahul C. Compositions and methods for topical delivery of oligonucleotides
EP1655021A1 (en) * 2004-11-09 2006-05-10 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
EP1891939A1 (en) * 2006-07-28 2008-02-27 Novagali Pharma SA Compositions containing quaternary ammonium compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096287A1 (en) * 1998-05-21 2005-05-05 Mehta Rahul C. Compositions and methods for topical delivery of oligonucleotides
EP1655021A1 (en) * 2004-11-09 2006-05-10 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
EP1891939A1 (en) * 2006-07-28 2008-02-27 Novagali Pharma SA Compositions containing quaternary ammonium compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EVANS ROBERT K ET AL: "Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines.", JOURNAL OF PHARMACEUTICAL SCIENCES JUL 2004, vol. 93, no. 7, July 2004 (2004-07-01), pages 1924 - 1939, XP002539854, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
WO2009063081A2 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
IL205320A0 (en) Compositions comprising an electrochemically altered fluid and a therapeutic agent and use thereof for treating lung or respiratory diseases
UA92584C2 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
WO2008041003A3 (en) Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorers asociated therewith
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
IL180565A0 (en) An improved stopcock for administering medicaments into the patient's body
WO2010014690A3 (en) Medical devices for therapeutic agent delivery
IL221795B (en) Use of a pharmaceutical composition of methylnaltrexone, or a salt thereof, in the preparation of a medicament for treating the side effects of opioid treatment
WO2007146426A3 (en) Nanoshells for drug delivery
EP2671584A3 (en) Compositions and methods for treating disorders associated with salt or fluid retention
WO2006099541A3 (en) Therapeutic wound care product
WO2008128740A8 (en) Titration of tapentadol
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MX2009002196A (en) Buprenophine-wafer for drug substitution therapy.
UA98136C2 (en) Use of aclidinium for the treatment of respiratory diseases
EP1938814A4 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
MX2009004561A (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
MX2009011900A (en) Diabetic wound healing.
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
SI1610787T1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from tiotropium salts for the treatment of respiratory diseases
MXPA05010161A (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases.
PT1220676E (en) PREVENTION OF COLORCECTAL CANCER
PL2640364T3 (en) Pharmaceutical composition comprising bicarbonate salt, and use thereof as a medicament in the treatment and/or prevention of urinary lithiasis and related diseases
WO2009063081A3 (en) Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08849479

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08849479

Country of ref document: EP

Kind code of ref document: A2